Objective: To determine the prevalence and clinical and genetic characteristics of patients with Xlinked Charcot-Marie-Tooth disease (CMT) due to mutations in noncoding regions of the gap junction b-1 gene (GJB1).
Mutations in the gap junction b-1 gene (GJB1) encoding the transmembrane channel protein, connexin 32 (Cx32), are the most common cause of X-linked Charcot-Marie-Tooth disease (CMTX) and the second commonest cause of Charcot-Marie-Tooth disease (CMT) overall. 1 The Cx32 protein is widely expressed in human tissues, including myelinating Schwann cells in the peripheral nervous system. 2 In the peripheral nervous system, Cx32 is found in the noncompact myelin of the paranodes and incisures, where it allows the movement of small molecules and ions between the multiple concentric myelinated layers of the Schwann cell and the axon membrane. 2, 3 GJB1 exists as 2 transcripts that are regulated by 2 tissue-specific promoters (P1 and P2), allowing differential expression of these transcripts in neuronal and non-neuronal tissue. [4] [5] [6] The transcriptional machinery in neuronal tissue requires the P2 promoter and other elements located in the 59 untranslated region (UTR) for efficient Cx32 expression. Mutations in the 59 UTR region have previously been described by our group and others as causative of CMTX1 and have been shown to impair P2mediated transcription of GJB1. 7 Mutations in the 39 UTR region are a rare cause of hereditary diseases overall; however, as this region often contains mRNA regulatory elements, mutations in the 39 UTR may affect normal translation. 8 In this study, we sought to determine the frequency and phenotype of CMTX1 due to mutations in the 59 and 39 UTR noncoding regions of GJB1. METHODS 
Patients. Patients harboring mutations in the 59
and 39 UTR of GJB1 were identified from the CMT database of the National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom. In some patients in whom Sanger sequencing of the coding region of GJB1 was negative, further screening of the 59 and 39 UTR was performed because of the strong clinical suspicion of CMT1X on the basis of a lack of male-to-male transmission, more severely affected males, and a predominantly demyelinating polyneuropathy. The remaining patients were identified from diagnostic samples submitted for testing of GJB1 to the neurogenetics laboratory of The National Hospital of Neurology and Neurosurgery after routine screening of both the coding and noncoding regions of GJB1 was adopted. The clinical and neurophysiologic data were collected retrospectively for all identified patients with mutations in the 59 and 39 UTR of GJB1. Genetics analysis. Genetic testing was performed in the National Hospital of Neurology and Neurosurgery Neurogenetics Laboratory. Additional targeted genetic testing was performed in selected cases (appendix e-1 at Neurology. org). Mutations were identified by bidirectional Sanger sequence analysis of GJB1 including 595 bases upstream of the ATG start codon, the coding region, and 25 bases of 39 UTR Pedigrees for the families reported in this study Black symbols 5 affected; empty symbols 5 unaffected; dot symbols 5 affected by history; diagonal line 5 deceased; arrow 5 index case. 
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Neurology 88 April 11, 2017 sequence. Conditions and primers are available in appendix e-1. In silico analysis was performed with the aid of AlamutVisual (Interactive Biosoftware, Rouen, France), which includes the splice-prediction tools SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder.
Standard protocol approvals, registrations, and patient consents. This study was approved by the research ethics committee of the National Hospital for Neurology and Neurosurgery. All patients consented to publication of their clinical details.
RESULTS Demographics. A total of 25 individuals from 10 kindreds with mutations in the 59 and 39 UTR of GJB1 were identified (figure 1), of whom 14 were male and 11 female. The age at onset was reported to be less than 10 years in 7 male participants and 1 female participant with a range of 5-32 years in male participants and 8-55 years in female participants. Four patients from family 1 (1-I.2, 1-II.2, 1-II.4, and 1-III.3) and all 4 patients from family 2 have been reported previously. 9 There was no male-tomale transmission in any of the pedigrees. Neuropathology. Sural nerve biopsy was available from 2 patients (1-II.2 and 2-III.3) and revealed a significant reduction in myelinated nerve fiber density and thin myelin sheaths (appendix e-1). There were occasional regeneration clusters and mild endoneurial edema. There were no inflammatory cells. These findings are similar to coding GJB1 mutation patients.
Genetic analysis. Five distinct mutations in the 59 and 39 UTR of GJB1 were identified (table 1) . The position of the mutations relative to the GJB1 open reading frame (ORF) region is shown in figure 2 . The nomenclature used in this study is based on current recommendations of the Human Genome Variation Society (HGVS). 11 In table e-2, there is an overview of all mutations in the 59 and 39 UTR regions of GJB1 and the corresponding nomenclature based on counting directly from the ATG translation initiation codon, which has been previously used to describe a number of mutations. The previously reported mutations 9, [12] [13] [14] [15] DISCUSSION In this study, we describe 2 new pathogenic mutations in the 59 UTR and a likely pathogenic mutation in the downstream 39 UTR region of GJB1. The evidence for the pathogenicity of these mutations is largely indirect and based on a typical CMT X1 phenotype, segregation within family members, in silico splice prediction analysis, and for the 39 UTR mutation, the presence of the same mutation in an unrelated individual with the same phenotype. All patients included in this study had a clinical or neurophysiologic phenotype typical for CMTX1 due to mutations in the GJB1 ORF region, characterized by a slowly progressive, predominantly length-dependent neuropathy, in which male participants were more severely affected than female participants and with an earlier age at onset. 21 In male participants, the motor CVs were in the intermediate range and slower than in female participants, as has been described previously. 22 Evidence suggests that loss of Cx32 channel function is the underlying pathomechanism responsible for CMTX1 due to coding mutations in GJB1. 23 The nerve-specific 59 UTR of GJB1 is located immediately upstream of the start codon, adjacent to the P2 promoter. The P2 promoter contains binding sites for the neuron-specific transcription factors SOX10 and EGR2 that strongly activate Cx32 expression in the peripheral nervous system. 7, 24 EGR2 has 3 proposed binding sites (E1, E2, and E3) within the P2 promoter, whereas SOX10 has 2 P2 binding sites (S1 and S2) (figure 2). Several mutations located within the core of the S2 SOX10 binding site have previously been described, a number of which have been shown to impair SOX10-mediated transcription of GJB1, resulting in a significant reduction in Cx32 expression. 7, 12, 25, 26 The novel c.-146-90_-146-89insT mutation is located within the E3 EGR2 binding site. The E2 and E3 binding sites of promoter P2 are responsible for the majority of EGR2-mediated transcriptions of GJB1. 24 It is therefore likely that this mutation results in reduced Cx32 expression as observed for mutations within the SOX10 binding site.
The c.-17G.A mutation was identified in 4 different families (1, 2, 4, and 9) and has previously been reported by our group. 9 This mutation is located in the last base of exon 1b, which is one of the most highly conserved bases in splice-site consensus sequences. In silico splice site analysis predicted that this mutation may reduce the efficiency of splicing at this intron/exon boundary, leading to the inclusion of intron 1 and a mutant transcript. 9 The second novel c.-1711G.T mutation in family 6 affects the adjacent base and is predicted to be pathogenic by the same mechanism.
We identified the c.-103C.T mutation in 2 different families (3 and 7) . This mutation has previously been reported in unrelated families. 12, 14, 15, 27 It is located within exon Ib, downstream of the P2 promoter, and lies within the internal ribosomal entry site (IRES) of the peripheral nerve specific mRNA transcript. The mutation is predicted to prevent translation of GJB1 mRNA. 28 Taken together, our study and previous reports provide strong evidence that the c.-103C.T is pathogenic. Of note, the c.-102G.A variant (reported as c.-458G.A), affecting the adjacent base, did not segregate in a large family with CMT, suggesting that not every variant of an IRES element is pathogenic. 29 Despite being located in a less conserved region, the mutation in the 39 UTR region, c.15C.T*, segregated in 2 unrelated families with a typical CMTX1 phenotype. This specific 39 UTR region contains sequences that are predicted to act as regulatory elements critical in Cx32 translational activation/ repression, mRNA stability, micro-RNA binding, and transcript localization. 8 Although our understanding of the role of these sequences is poor, in silico splicing analysis predicts that this variant may create a 59 donor splice site leading to aberrant splicing within the 39 UTR. This in turn may affect mRNA stability, leading to downregulation of GJB1 expression.
The clinical and electrophysiologic findings of the patients described in this article with point mutations within S2 SOX10 and E3 EGR2 are indistinguishable from patients with mutations in the ORF of GJB1. Previous in vitro analysis of the c.-146-27T.C (c.-529T.C) mutation in the E3 region or deletion of the S2 region have demonstrated a partial loss of promoter activity. 7, 24 The indistinguishable clinical phenotype of the patients included in this study from patients with complete loss of function mutations in GJB1 suggests that the noncoding mutations described cause complete loss of function.
In this study, we describe 5 pathogenic mutations, 3 of which are novel, in noncoding regions of GJB1, which are predicted to result in loss of function by a combination of transcription factor binding, disruption of mRNA translation, and altered mRNA stability. The search for these noncoding mutations was largely driven by the recognition of the classical phenotype of CMTX1 in the absence of mutations in the coding regions of GJB1. The large number of noncoding mutations in GJB1 (11.4% of our cohort of 219 GJB1 patients) is of interest and highlights the importance of mutations in noncoding DNA in human disease and the need to include noncoding regions of GJB1 in targeted inherited neuropathy gene panels.
The study also raises the possibility that these types of mutations may be a more frequent cause of other inherited neurologic conditions than has been previously appreciated including in the not infrequent situation where next-generation sequencing identifies a heterozygous mutation for a gene known to cause recessive disease. How frequent similar noncoding mutations will be in other hereditary neuropathies and other inherited neurologic diseases has yet to be determined.
